期刊文献+

髓过氧化物酶基因多态性与原发性高血压遗传易感性的研究 被引量:1

Gene polymorphism of myeloperoxidase and genetic susceptibility to essential hypertension
原文传递
导出
摘要 目的:研究髓过氧化物酶(MPO)基因多态性与原发性高血压(EH)之间的遗传易感性。方法:采用分子流行病学方法,应用聚和酶链反应检测法107例EH和97例健康对照MPO基因型,比较不同基因型之间的分布频率及95%可信区间(CI),分析MPO基因多态性与EH易感性的关系。结果:正常人群GG、GA、AA基因型频率分别为56.7%、40.2%和3.1%,EH组分别为70.1%、29.0%和0.9%。携带GG者患EH的风险是基因型为至少一个等位基因A者的1.79倍(95%CI1.005~3.186)。结论:本研究人群MPO基因多态与EH遗传易感性相关,等位基因A对EH易感性有保护作用。 Objective: To investigate the association between gene polymorphism of myeloperoxidase and genetic susceptibility to essential hypertension in Chinese population. Method: MPO genotypes in 107 cases of essential hypertension and 97 persons of healthy control were detected using PCR-restriction fragment length polymorphism assay (PCR RFLP) in a case control molecular epidemiology study. The association between this gene polymorphism and the risk of essential hypertension in Chinese population was examined through comparing odds ratio (OR) and 95 confidence interval (CI) between two groups. Result: In healthy control group, the frequencies of G/G, G/A, and A/ A genotypes were 56. 7 %,40.2 % and 3.1 %, respectively. In essential hypertension group, the frequencies of the persons carrying above three genotypes were 70.1 %, 29.0 % and 0.9 %, respectively. The risk of Essential Hypertension for person carrying G/G genotype was 1.79 fold of the persons carrying at least one A allele (95% CI 1. 005- 3. 186). Conclusion: MPO gene polymorphism was associated with susceptibility of essential hypertension in Chinese population. The risk of essential hypertension was decreased in the persons carrying allele A.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2009年第3期202-204,共3页 Journal of Clinical Cardiology
关键词 高血压 髓过氧化物酶 基因多态 遗传易感性 hypertension gene polymorphism myeloperoxidase genetic susceptibility
  • 相关文献

参考文献12

  • 1YUSUF S, REDDY S, OUNPUU S, et al. Global burden of cardiovascular diseases: part Ⅰ: general considerations, the epidemiologic transition, risk factors, and impact of urbanization[J]. Circulation, 2001,104 : 2746-2753.
  • 2BRENNAN M L,. HAZEN S L. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment[J]. Curr Opin Lipidol, 2003, 14:353-359.
  • 3LONDON S J, LEHMAN T A, TAYLOR J A. Myeloperoxidase genetic polymorphism and lung cancer [J]. Cancer Res,1997,57:5001-5003.
  • 4SCHABATH M B, SPITZ M R, HONG W K, et al. A myeloperoxidase polymorphism associated with reduced risk of lung cancer[J]. Lung Cancer, 2002,37: 35-40.
  • 5EISERICH J P, BALDUS S, BRENNAN M L, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase[J]. Science, 2002,296 ; 2391 - 2394.
  • 6PRASAD A, ZHU J, HALCOX J P, et al. Predisposition to atherosclerosis by infections:role of endothelial dysfunction[J]. Circulation, 2002,106 :184-190.
  • 7VITA J A, BRENNAN M L, GOKCE N, et al. Serum myeloperoxidase level independently predicts endothelial dysfunction in humans [ J ]. Circulation, 2004,110 : 1134-1139.
  • 8GAUGHAN D J, KLUIJTMANS L A, BARBAUX S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations[J]. Atherosclerosis, 2001,157:451-456.
  • 9STEPHAN B, CHRISTOPHER H, THOMAS, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes[J]. Circulation, 2003,108 : 1440-1445.
  • 10ASSELBERGS F W, TERVAERT J W, TIO R A. Prognostic value of myeloperoxidas in patients with chest pain[J]. N Egnl J Med, 2004,350:516-518.

二级参考文献9

  • 1DAUGHERTY A,DUNN J L,RATERI D L,et al.Myeloperoxidase,a catalyst for lipoprotein oxidation,is expressed in human atherosclerotic lesions[J].J Clin Invest,1994,94:437-444.
  • 2NIKPOOR B,TURECKI G,FOURNIER C,et al.A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians[J].Am Heart J,2001,142:336-339.
  • 3BRENNAN M L,PENNMS M S,VAN LENTE F,et al.Prognostic value of myeloperoxidase in patients with chest pain[J].N Engl J Med,2003,349:1595-1604.
  • 4CARR A C,MCCALL M R,FREI B.Oxidation of LDL by myeloperoxidase and reactive nitrogen species[J].Arterioscler Thromb Vasc Biol,2000,20:1716-1723.
  • 5ZHENG L,NUKUNA B,BRENNAN M L,et al.Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease[J].J Clin Invest,2004,114:529-541.
  • 6BERGT C,PENNATHUR S,FU X,et al.The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport[J].Proc Natl Acad Sci USA,2004,101:13032-13037.
  • 7SUGIYAMA S,KUGIYAMA K,AIKAWA M,et al.Hypochlorous acid,a macrophage product,induces endothelial apoptosis and tissue factor expression:involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis[J].Arterioscler Thromb Vasc Biol,2004,24:1309-1314.
  • 8RUTGERS A,HEERINGA P,GIESEN J E,et al.Neutrophil myeloperoxidase activity and the influence of two single-nucleotide promoter polymorphisms[J].Br J Haematol,2003,123:536-538.
  • 9CASCORBI I,HENNING S,BROCKMOLLER J,et al.Substantially reduced risk of cancer of aerodigesrive tract in subjects with variant -463A of the myeloperoxidase gene[J].Cancer Res,2000 60:644-649.

共引文献5

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部